Programmed Release of Dihydroartemisinin for Synergistic Cancer Therapy Using a CaCO₃ Mineralized Metal–Organic Framework

Abstract

Dihydroartemisinin (DHA) has attracted increasing attention as an anticancer agent. However,using DHA to treat cancer usually depends on the synergistic effects of exogenous components,a nd the loss of DHA during delivery reduces its effectiveness in cancer therapy. Reported herein is ap rogrammed release nanoplatform of DHA to synergistically treat cancer with aF e-TCPP [(4,4,4,4-(porphine-5,10,15,20-tetrayl) tetrakis(benzoic acid)] NMOF (nanoscale MOF) having aC aCO 3 mineralizedc oating, whichp revents DHA leakage during transport in the bloodstream. When the nanoplatform arrives at the tumor site,t he weakly acidic microenvironment and high concentration of glutathione (GSH) trigger DHA release and TCPP activation, enabling the synergistic Fe 2+ -DHA-mediated chemodynamic therapy, Ca 2+ -DHA-mediated oncosis therapy, and TCPP-mediated photodynamic therapy.In vivo experiments demonstrated that the nanoplatform showed enhanced anticancer efficiency and negligible toxicity.

A redox-responsive dihydroartemisinin dimeric nanoprodrug for enhanced antitumor activity

“…For the past few years, traditional herbal medicines have generated many chemotherapy drugs which could inhibit a variety of tumor entities [ 5 ]. For instance, dihydroartemisinin (DHA), one derivative of artemisinin, has been proved to possess a potent and broad anti-tumor effect in addition to anti-malarial [ 6 – 9 ]. However, some existing problems, for example strong hydrophobicity, nonspecific distribution, and rapid elimination from the body, impede the application of DHA in cancer treatment [ 10 – 12 ].…”

Multifunctional Bismuth Ferrite Nanocatalysts with Optical and Magnetic Functions for Ultrasound-Enhanced Tumor Theranostics

“…[6][7][8][9] The nanostructures that can be responsive to peculiar tumor microenvironment (TME) not only possess high functionality and selectivity, but also insignificant invasiveness. [10][11][12][13][14][15][16][17][18][19][20][21][22] Unluckily, the therapeutic efficacy of CDT is confined due to the inadequate Fenton reaction efficiency in weakly acidic TME, on account of the rigorous Fenton reaction condition, limiting its further biological applications. [23][24][25][26] As a consequence, how to increase the therapeutic efficacy of Fenton reaction in tumor is the primary problem of CDT at present.…”

A pH-responsive ultrathin Cu-based nanoplatform for specific photothermal and chemodynamic synergistic therapy

“…The ROS generation in cells was evaluated by selecting 2 0 ,7 0 -dichlorodihydrouorescein diacetate (DCFH-DA) as a uorescent probe. 47 Corresponding confocal laser scanning microscopy (CLSM) images of Hela cells treated with CuFe-LDHs and GOD/CuFe-LDHs at pH ¼ 7.4 and 6.5 were acquired (Fig. 4D), and the results revealed that cells treated with GOD/CuFe-LDHs at pH ¼ 6.5 exhibited the strongest uorescence signal, indicating the highest ROS production.…”